332 related articles for article (PubMed ID: 18762220)
1. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
[TBL] [Abstract][Full Text] [Related]
2. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
[TBL] [Abstract][Full Text] [Related]
3. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.
Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP
Clin Exp Allergy; 2010 Jun; 40(6):933-41. PubMed ID: 20184606
[TBL] [Abstract][Full Text] [Related]
4. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
5. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
Feunou PF; Kammoun H; Debrie AS; Locht C
Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
[TBL] [Abstract][Full Text] [Related]
6. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
8. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
[TBL] [Abstract][Full Text] [Related]
9. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
Lim A; Ng JK; Locht C; Alonso S
Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
[TBL] [Abstract][Full Text] [Related]
10. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R
Vaccine; 2014 Jun; 32(27):3350-6. PubMed ID: 24793938
[TBL] [Abstract][Full Text] [Related]
11. Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.
Kammoun H; Feunou PF; Foligne B; Debrie AS; Raze D; Mielcarek N; Locht C
Vaccine; 2012 Aug; 30(40):5864-70. PubMed ID: 22814407
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
[TBL] [Abstract][Full Text] [Related]
13. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.
Fedele G; Bianco M; Debrie AS; Locht C; Ausiello CM
J Immunol; 2011 May; 186(9):5388-96. PubMed ID: 21430219
[TBL] [Abstract][Full Text] [Related]
14. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
Mielcarek N; Debrie AS; Mahieux S; Locht C
Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
[TBL] [Abstract][Full Text] [Related]
15. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
[TBL] [Abstract][Full Text] [Related]
16. Live attenuated Bordetella pertussis vaccine candidate BPZE1 transiently protects against lethal pneumococcal disease in mice.
Belcher T; Kammoun H; Coutte L; Debrie AS; Mielcarek N; Sirard JC; Cauchi S; Locht C
Vaccine; 2022 Mar; 40(11):1555-1562. PubMed ID: 33509692
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults.
Buddy Creech C; Jimenez-Truque N; Kown N; Sokolow K; Brady EJ; Yoder S; Solovay K; Rubin K; Noviello S; Hensel E; Selamawi S; Bakare A; Makowski M; Lu K
Vaccine; 2022 Nov; 40(47):6740-6746. PubMed ID: 36220716
[TBL] [Abstract][Full Text] [Related]
18. Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.
Solans L; Debrie AS; Coutte L; Locht C
Vaccine; 2021 May; 39(21):2843-2849. PubMed ID: 33896662
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C
PLoS One; 2014; 9(1):e83449. PubMed ID: 24421886
[TBL] [Abstract][Full Text] [Related]
20. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen.
Mooi FR
Infect Genet Evol; 2010 Jan; 10(1):36-49. PubMed ID: 19879977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
